Cargando…
Comparison clinical and metabolic effects of metformin and pioglitazone in polycystic ovary syndrome
INTRODUCTION: Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women. PCOS comprises a broad spectrum of anomalies, including hyperandrogenism, chronic anovulation, obesity, and infertility. Insulin resistance and its compensatory hyperinsulinemia play a key role in...
Autores principales: | Shahebrahimi, Karoon, Jalilian, Nasrin, Bazgir, Nasrin, Rezaei, Mansour |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5105565/ https://www.ncbi.nlm.nih.gov/pubmed/27867884 http://dx.doi.org/10.4103/2230-8210.192925 |
Ejemplares similares
-
Leptin and body mass index in polycystic ovary syndrome
por: Jalilian, Nasrin, et al.
Publicado: (2016) -
Metabolomics Reveals Reduction of Metabolic Oxidation in Women with Polycystic Ovary Syndrome after Pioglitazone-Flutamide-Metformin Polytherapy
por: Vinaixa, Maria, et al.
Publicado: (2011) -
Evaluating the effect of insulin sensitizers metformin and pioglitazone alone and in combination on women with polycystic ovary syndrome: An RCT
por: Sohrevardi, Seyed Mojtaba, et al.
Publicado: (2016) -
Low-Dose Spironolactone-Pioglitazone-Metformin Normalizes Circulating Fetuin-A Concentrations in Adolescent Girls with Polycystic Ovary Syndrome
por: Díaz, Marta, et al.
Publicado: (2018) -
Interaction between OCT1 and LPIN1 polymorphisms and response to pioglitazone-metformin tablets in patients with polycystic ovary syndrome
por: Zeng, Haixia, et al.
Publicado: (2023)